ADCENDO
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
ADCENDO
Social Links:
Industry:
Biotechnology Health Care
Founded:
2017-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.adcendo.dk
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
114.58 M USD
Technology used in webpage:
Google Font API WordPress LetsEncrypt Font Awesome Wordpress Plugins LiteSpeed Lightspeed Cache Team.blue Under Construction For WordPress
Similar Organizations
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
SalubrisBio
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing novel antibody and protein-based therapeutics.
Current Advisors List
Current Employees Featured
Founder
Investors List
Gilde Healthcare
Gilde Healthcare investment in Series A - ADCendo
RA Capital Management
RA Capital Management investment in Series A - ADCendo
Ysios Capital
Ysios Capital investment in Series A - ADCendo
Novo Holdings
Novo Holdings investment in Series A - ADCendo
Dawn Biopharma
Dawn Biopharma investment in Series A - ADCendo
Pontifax
Pontifax investment in Series A - ADCendo
HealthCap
HealthCap investment in Series A - ADCendo
Novo Holdings
Novo Holdings investment in Series A - ADCendo
RA Capital Management
RA Capital Management investment in Series A - ADCendo
HealthCap
HealthCap investment in Series A - ADCendo
Key Employee Changes
| Date | New article |
|---|---|
| 2023-06-20 | Lone Ottesen named Adcendo CMO |
| 2022-05-03 | Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer |
Official Site Inspections
http://www.adcendo.dk
- Host name: linux25.curanet.dk
- IP address: 185.21.41.51
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "ADCendo"
About Adcendo
Adcendo is a global clinical-stage biotech company dedicated to developing transformative first and best-in-class antibody-drug conjugate (ADC) therapies for cancers with high unmet medical need. We are headquartered in …See details»
ADCendo - Crunchbase Company Profile & Funding
Contact Email [email protected] ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug …See details»
The Story - Adcendo
Adcendo was founded in 2017 as a spin-out from The University of Copenhagen and Rigshospitalet. The scientific founders, Niels Behrendt, Lars Engelholm and Christoffer Nielsen from The Finsen Laboratory, had just recently published …See details»
ADCendo ApS - 38780093 - Frederiksberg - Se Regnskaber, Roller …
Proff.dk (DA) Log ind. Log ind Søg. Vælg branche Segmentering. Sammenlign. Netværkssøgning Toplister Mere. Annonce. ADCendo ApS. CVR-nr 38780093 CVRP-nr 1022633763. Adresse …See details»
Adcendo - LinkedIn
Adcendo | 7.346 følgere på LinkedIn. Development of highly differentiated first-in-class antibody-drug conjugates (ADCs) for treatment of solid tumors. | Adcendo is a Danish clinical-stage …See details»
Adcendo ApS Announces Changes in Board of Directors and
4 days ago COPENHAGEN, Denmark, April 1, 2025 /CNW/ -- Adcendo, a biotech company pioneering the development of first- and potential best-in-class antibody-drug conjugates …See details»
Adcendo 2025 Company Profile: Valuation, Funding
Adcendo General Information Description. Developer of antibody-drug conjugates designed to create new medicines for cancer patients with significant unmet needs. The company's conjugates are directed at a target receptor, which is …See details»
Adcendo, Company at 3 Ole Maaløes Vej, Copenhagen, …
Adcendo is a company, located at 3 Ole Maaløes Vej, Copenhagen, Capital Region of Denmark 2200, Denmark. Visit their website www.adcendo.com or LinkedIn profile for more detailed …See details»
Adcendo (Denmark) Funding: $249.6M - Medical Startups
Nov 25, 2024 Denmark | Funding: $249.6M Website: https://adcendo.dk/ ADCendo is dedicated to developing antibody-drug conjugates (ADCs) for treatment of cancer. We are taking the …See details»
Novo Seeds co-leads Adcendo’s EUR 51 Million Series …
Apr 29, 2021 About Adcendo ApSAdcendo ApS, a spin-out from the University of Copenhagen and Rigshospitalet and previously part of the BioInnovation Institute’s Creation House Program, is developing novel antibody-drug …See details»
ADCendo Company Profile - Office Locations, Competitors ... - Craft
ADCendo Summary. Company Summary. Overview. ADCendo is a biotech company dedicated to developing anti-cancer drugs. It is focused on antibody-drug conjugates (ADCs) directed at …See details»
Adcendo ApS Announces Changes in Board of Directors and …
5 days ago COPENHAGEN, Denmark, April 1, 2025 /PRNewswire/ -- Adcendo, a biotech company pioneering the development of first- and potential best-in-class antibody-drug …See details»
Adcendo ApS - 38780093 - Frederiksberg - Se Regnskaber, Roller …
Proff.dk giver dig firmainformation om Adcendo ApS, 38780093. Find kontaktinfo, regnskabstal, ledelse, bestyrelse og ejere. Markedspakker. Alle produkter. ... Juridisk navn ADCendo ApS …See details»
Adcendo Company Information - Funding, Investors, and More
Track over 71,000 companies. Discover Fast-growing Global startups. Seedtable uses technology and people to track over 71,000 companies to help you find the right ones to partner with.See details»
Press releases - Adcendo
Oct 8, 2024 Copenhagen, Denmark, October 29th, 2024 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of first-in-class ADCs for the treatment of cancers with …See details»
Danish Adcendo announces oversubscribed US 135 million Series …
Dec 13, 2024 Founded in 2017 and headquartered in Copenhagen, Adcendo is a Danish biotech company specialising in the development of antibody-drug conjugates (ADCs) for treatment of …See details»
Adcendo raises EUR 51 Million in Series A Financing to Advance …
COPENHAGEN, Denmark, April 29, 2021 /PRNewswire/ -- Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced …See details»
adcendo - Overview, News & Similar companies | ZoomInfo.com
Jan 5, 2023 View adcendo (www.adcendo.dk) location in Capital Region, Denmark , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
ADCendo ApS: Trojansk kemo-behandling slår kræftceller ihjel …
Web: www.adcendo.dk. Innofounder: Christoffer Nielsen. Nyhedsbrev. Tilmeld dig fondens nyhedsbrev og få de seneste nyheder om fondens investeringer. Navn. Mail.. Accepter …See details»
Adcendo Series A Press Release
Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers. Financing led by Novo Seeds and Ysios Capital is …See details»